Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
On Tuesday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $3.83 which represents a decrease of $-0.47 or -10.93% from the prior close of $4.3. The stock opened at $4.32 and ...
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
That was the case this morning with once high-flying stock Cassava Sciences (SAVA). This is a stock that once skyrocketed to $146. A little over three years later, this thing closed the day at $4.30, ...
Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints: Austin, Texas Wednesday, November 27, 2024, 18:00 Hrs [IST] C ...
Zacks.com on MSN23h
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage StudyCassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
Initial results from Harvard reveal high levels of mercury in the Madeira, although still below the limit recommended by ...
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback